Table 4.

Drugs and classes of medical agents used for NFPAs.

Classes of medications	References
Dopamine agonists (DA)	62, 76-80
Somatostatin receptor ligands (SRLs)	81-85
Combination treatment with SRLs plus DAs	85
Temozolomide (TMZ)	86-89
Peptide receptor radionuclide therapy (PRRT)	86, 90-93
Gonadotrophin-releasing hormone (GnRH) receptor agonists and antagonists	62
Octreotide-mediated tumour-targeted cytotoxic drug delivery	94, 95
Folate receptor-mediated drug targeting	32, 96-98
Targeting of PI3K/AKT/mTOR pathway	99, 100-104